StockData
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd (RGC) stock

RGCNasdaqMedicinal Chemicals & Botanical Products
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.55−0.17 (-3.60%)

Close on Nov 17, 2026Market cap $2.26BP/E –Yield –

Regencell Bioscience enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Regencell Bioscience's enterprise value was $2.67B on Nov 11, 2026, against $5.70B a year earlier. Over the last 5 years it ranged from $32.11M to $14.45B, with a median of $344.03M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$2.67B-74.3%
2025Dec 31, 2025$10.38B+18328.5%
2024Dec 31, 2024$56.32M-54.9%
2023Dec 29, 2023$125.02M-63.9%
2022Dec 30, 2022$346.50M+8.8%
2021Dec 31, 2021$318.46M–

More Regencell Bioscience figures

See a number that looks wrong?